



## Assisted Breathing with a Diaphragm Pacing System: A Systematic Review

A-la Woo<sup>1</sup>, Ha-jin Tchoe<sup>2</sup>, Hae-won Shin<sup>2</sup>, Chae-min Shin<sup>2</sup>, and Chae-Man Lim<sup>1</sup>

<sup>1</sup>Division of Pulmonary and Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul;

<sup>2</sup>Division for New Technology Assessment, National Evidence-Based Healthcare Collaborating Agency, Seoul, Korea.

**Purpose:** Patients with respiratory failure associated with neurological dysfunction often require mechanical ventilator support, which poses increased economic burden and ventilator-associated complications. A diaphragm pacing system (DPS) is an implanted device that provides respiratory support for such patients. In this systematic review, we reviewed the literature to assess the safety and efficacy of DPS for patients with respiratory failure resulting from amyotrophic lateral sclerosis (ALS) or cervical spinal cord injuries.

**Materials and Methods:** The following databases were searched from July 10 to July 30, 2018: MEDLINE, EMBASE, Cochran library, KoreaMed, Research Information Sharing Service, Korean studies Information Service System, Korea Institute of Science and Technology Information, and Korean Medical database. The abstracts and full texts of the searched articles were reviewed by two reviewers.

**Results:** The search keywords generated 197 articles: two randomized controlled trials, two case-control studies, and one case report involving patients with ALS; one cohort study, one case-control study, and two case reports involving patients with cervical spine injury; and one case report involving patients with both conditions were included. The primary outcome was safety profile (complications and adverse event) and efficacy (overall survival and sleep improvement). Complications and adverse events were more common in patients with ALS and spinal cord injury receiving DPS than in controls. Efficacy outcomes were inconsistent across ALS studies.

**Conclusion:** Based on safety and efficacy results, we do not support using DPS to manage respiratory failure in patients with ALS or cervical spine injury.

**Key Words:** Amyotrophic lateral sclerosis, spinal cord injury, electrical stimulation therapy, diaphragm

### INTRODUCTION

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects respiratory muscles and eventually requires respiratory assistance.<sup>1</sup> Like patients with ALS,

patients with cervical spinal cord injury commonly have compromised respiration, causing morbidity and mortality.<sup>2</sup> Mechanical ventilation can be used in those patients to support respiratory function<sup>3,4</sup> and alleviate sleep disorders.<sup>5</sup> It is, however, costly, requires continuous monitoring, and is associated with several complications.<sup>6,7</sup> Hence, clinicians must endeavor to prevent respiratory failure, a major cause of mortality in patients with ALS and spinal cord injury,<sup>8</sup> while deferring the need for mechanical ventilation as long as possible.<sup>4</sup>

Diaphragm pacing is a technique with a history of over a half-century for respiratory assistance.<sup>9</sup> Diaphragm pacing provides respiratory support by stimulating diaphragm contractions with electrical impulses generated by implanted electrodes (Fig. 1). Diaphragm pacing systems (DPS) using various surgical techniques have been developed. Of these, the United States Food and Drug Administration (FDA) has approved the

**Received:** May 11, 2020 **Revised:** October 5, 2020

**Accepted:** October 22, 2020


**Corresponding author:** Chae-Man Lim, MD, PhD, Division of Pulmonary and Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea.

Tel: 82-2-3010-6809, Fax: 82-2-3010-6968, E-mail: cmlim@amc.seoul.kr


•The authors have no potential conflicts of interest to disclose.

© Copyright: Yonsei University College of Medicine 2020

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<https://creativecommons.org/licenses/by-nc/4.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.



**Fig. 1.** Diaphragm pacing system. (A) Simplified presentation of a diaphragm system. The electrode is implanted in the diaphragm and connected to the stimulator. The stimulator provides an electrical impulse to the patient's diaphragm, causing it to contract and create respiration. Figure created in the Mind the Graph platform (<https://mindthegraph.com/>). (B) Image of an actual stimulator device connected to a patient. Adapted from Synapse Biomedical. NeuRx Diaphragm Pacing System™: patient/caregiver instruction manual.<sup>35</sup>



**Fig. 2.** Implantation procedure for diaphragm pacing. Under general anesthesia, the camera, laparoscopic implant tool, and mapping probes are inserted through four trocars into the patient's abdominal cavity (A). The mapping procedure is achieved by electrical stimulation of the diaphragm with a probe. After mapping of the diaphragm, the electrode is inserted laparoscopically (B). The implanted electrodes in each diaphragm (C). Figure created in the Mind the Graph platform (<https://mindthegraph.com/>).

following two devices: the NeuRx DPS™ Diaphragm Pacing System and the NeuRx RA/4 (Synapse Biomedical Inc., Cincinnati, OH, USA), both of which are implanted via laparoscopy.<sup>10</sup> The implantation procedure includes mapping proper position of the electrode by electrical stimulation of the diaphragm and implantation using a laparoscopic inserting device (Fig. 2). Phrenic nerve function should be preserved to make the diaphragm muscle contract. This stimulation not only provide respiratory support but also may delay respiratory muscle atrophy.<sup>11</sup> Moreover, with most patients with ALS patients suffering from sleep deprivation, diaphragm pacing may improve their sleep quality.<sup>12</sup> Nowadays, DPS has been widely

adopted for cervical spinal injuries and to manage respiratory dysfunction from neurodegenerative diseases, such as ALS.<sup>13</sup>

As the procedure should be performed under general anesthesia, risks from anesthesia and concerns of procedure-related complications have hindered the use of diaphragm pacing in patients with neurological problems. Moreover, there are questions regarding the clinical efficacy of DPS (survival, respiratory outcome, and sleep parameters).<sup>14</sup> Thus, multiple studies have sought to investigate the efficacy and safety of DPS in patients with ALS and spinal cord injuries. However, these studies have reported inconsistent results.

This systematic review summarizes the results of studies that

have reported on the safety and efficacy of DPS in patients with ALS or cervical spinal cord injuries with preserved phrenic nerve function.

## MATERIALS AND METHODS

### Data sources and literature search

The present review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses reporting guidelines and included literature written in English and Korean. A literature search was performed from July 10, 2018 to July 30, 2018 using the following databases: Ovid-MEDLINE, Ovid-EMBASE, Cochran Library, KoreaMed, Research Information Sharing Service, Korean studies Information Service System, Korea Institute of Science and Technology Information, and Korean Medical database. The following keywords were used: diaphragm pacing, phrenic pacing, DPS, intramuscular diaphragmatic stimulation, ALS, spinal cord injury, and quadriplegia. The detailed search methods and keywords used for each database are provided in Supplementary Table 1 (only online).

### Study selection

We selected studies in accordance with the Population, Intervention, Comparison, Outcome guidelines, based on our target conditions (ALS and spinal cord injury), intervention (self-breathing-assisted therapy with a DPS), comparator (sham treatment or mechanical ventilation), and outcome (mortality,

ventilator weaning, duration of self-respiration after operation, quality of life, operation time, hospital days after operation, and improvement in respiration).


Studies were excluded if they 1) involved animal or preclinical experiments, 2) were not original articles or were grey literature, 3) were published in languages other than English or Korean, 4) were systematic reviews that used a different methodology from the current review, 5) involved study subjects different from the present study, 6) involved a system other than the DPS, 7) used an implantation procedure other than laparoscopy, 8) did not report a clinical outcome, 9) involved duplicated subjects, 10) were duplicated articles, or 11) were unavailable as original articles.

### Study quality assessment

Study quality was assessed independently by the two reviewers using the methodology check list of the Scottish Intercollegiate Guidelines Networks and reported as a grade (Supplementary Table 2, only online). If there was disagreement between the reviewers, consensus was reached through committee discussion.

### Data extraction

Using a data extraction form (Supplementary Table 3, only online), two independent reviewers extracted the safety and efficacy profiles, the intervention used in the study, the characteristics of the study population, and the study outcomes.



**Fig. 3.** Flowchart of study selection. RISS, research information sharing service; KISS, Korean studies information service system; KISTI, Korea institute of science and technology information; KMBASE, Korean medical database.

## Data analysis

The safety (occurrence of complications and adverse events) and efficacy (sleep quality, patient survival, ventilator weaning, and quality of life) results for ALS, spinal cord injury, or both were analyzed by two reviewers using the quality analysis method.

## RESULTS

### Study selection

The overall process of literature search and selection is presented in Fig. 3. In total, 300 articles were identified. After duplicates were removed, the abstract and full text of 197 articles were reviewed. Ultimately, 10 articles were included in the review. Additional details about the included articles and the results of quality assessment are presented in Table 1. Among the reviewed studies, seven studies were non-analytic case reports (level of evidence with 3), one was a cohort study with risk of confounding (level 2-), and two were randomized controlled trials (RCTs) with a high level of evidence (1+).

### Safety

#### *Amyotrophic lateral sclerosis*

Two RCTs,<sup>15,16</sup> two case reports,<sup>17,18</sup> and one cohort study<sup>19</sup> reported procedure-related mortality, complications, adverse events, and/or failure of device implantation in patients with ALS (Table 2, 3). No studies reported a safety outcome as a primary endpoint. Therefore, we compared safety outcomes using the reported complications. In one RCT,<sup>16</sup> serious adverse events and complications were not significantly different between the intervention (diaphragm pacing with active stimulation) and control (sham stimulation) groups (Table 2). The other RCT<sup>15</sup> compared patients who received DPS plus non-invasive ventilation (intervention group) with those who received non-invasive ventilation only (control group). The total number of complications was higher in the intervention group than in the control group (78% vs. 3%). Further, adverse events were more common for all organ systems in the intervention group than in the control group (Table 2). However, although overall complications were more common in the intervention groups than in the control groups, serious adverse events, such as procedure-related mortality, were not reported for either RCT. Failure of device implantation was only reported in one case report.

#### *Spinal cord injury*

Only two cohort studies<sup>19,20</sup> described the safety outcomes of DPS in patients with spinal cord injury. The safety outcomes were defined as perioperative mortality, complications and adverse events, and failure of device implantation. No perioperative mortality occurred in the study regarding 50 cases.<sup>19</sup>

**Table 1.** Summary of Studies Selected for Review

Author (yr)	Study design	Country	Subjects (n)	Intervention	Control*	DPS device	Primary study outcome	Q
Gonzalez-Bermejo, et al. (2016) <sup>16</sup>	Multicenter, triple-blind RCT	France	ALS (74)	Active stimulation with DPS	Sham	NeuRx RA/4	Non-invasive ventilation free day survival	1+
DiPALS Writing Committee (2015) <sup>15</sup>	Multicenter, open-label, RCT	UK	ALS (74)	DPS and MV	MV	NeuRx RA/4	Overall survival	1+
Rezania, et al. (2014) <sup>18</sup>	Case series	USA	ALS (2)	DPS	NA	NS	Complication after DPS	3
Gonzalez-Bermejo, et al. (2012) <sup>21</sup>	Prospective, non-randomized, multicenter, interventional trial	France	ALS (18)	DPS	NA	NeuRx DPSTM	Impact of the DPS on decline of forced vital capacity	3
Kotan, et al. (2016) <sup>17</sup>	Case-report	Turkey	ALS (1)	DPS	NA	NS	Sleep quality after DPS	3
Watt, et al. (2011) <sup>22</sup>	Retrospective cohort study	UK	ASI, Quadriplegia (19)	DPS	MV	NS	Overall survival	2-
Onders, et al. (2011) <sup>20</sup>	Prospective, non-randomized, single-center, interventional trial*	USA	SCI (6)	DPS	NA	NS	Time on ventilator, Pacing achieved time	3
Bolikai, et al. (2012) <sup>36</sup>	Case series	USA	CSI (4)	DPS	NA	Atrostim	Respiratory function	3
Epstein, et al. (1979) <sup>37</sup>	Case series	Canada	CSI (3)	DPS	NA	Atrostim	Respiratory function	3
Onders, et al. (2009) <sup>19</sup>	Case-study	USA	ALS, SCI (88)	DPS	NA	NeuRx RA/4	Comparison of perioperative mortality and morbidity between SCI and ALS	3

ALS, amyotrophic lateral sclerosis; RCT, randomized controlled trial; DPS, diaphragm pacing system; MV, mechanical ventilation; SCI, spinal cord injury; CSI, cervical spine injury; ASI, acute spinal injury; Q, quality assessment; NS, not specified; NA, no data available.  
\*Pediatric cases. †The subjects of this study were patients with spinal cord injury; the primary outcome was a comparison of survival between patients on ventilator support prior to discharge and ventilator-weaned patients. The comparison of diaphragm pacing and mechanical ventilation was a sub-group analysis. ‡This was an ancillary study to RespiStimALS17 (NCT01583088) using the cohort of DPS-implanted patients at the French participating center.

**Table 2.** Complications and Adverse Events in Randomized Controlled Trials with Amyotrophic Lateral Sclerosis Patients

Author (yr)	No. of subjects	Follow-up duration (yr)	Type of complication	Intervention group (n=37) (% , n)	Control group (n=37) (sham, % , n)
Gonzalez-Bermejo, et al. (2016) <sup>16</sup>	74	3.75	Organ damage during surgical procedure	0	8 (3)
			Pneumothorax or capnothorax	5 (2)	5 (2)
			Acute respiratory distress syndrome	19 (7)	19 (7)
			Venous thromboembolism	5 (2)	3 (1)
			Percutaneous endoscopic gastrostomy	19 (7)	24 (9)
			Serious adverse event	59 (22)	65 (24)
DiPALS Writing Committee (2015) <sup>15</sup>	74	1	Respiratory system	68 (25)	38 (14)
			Respiratory infection	35 (12)	19 (7)
			Respiratory failure	27 (10)	14 (5)
			Respiratory distress	11 (4)	5 (2)
			Pneumothorax or capnothorax	14 (5)	0
			Airway obstruction, pulmonary thromboembolism, cough	3 (1)	0
			Pain	27 (10)	16 (6)
			Gastrointestinal system	27 (10)	24 (9)
			Motoneuron symptoms	22 (8)	8 (3)
			Genitourinary system	8 (3)	8 (3)
			Dermatologic system	8 (3)	11 (4)
			Cardiovascular system	11 (4)	5 (2)
			Psychiatric	11 (4)	0
			Central nerve system	3 (1)	3 (1)
			Insertion or removal of PEG or PIG tube	14 (5)	24 (9)
			Infection of PEG or PIG	8 (3)	3 (1)
			Wire problems	14 (5)	0
			Mechanical ventilation	8 (3)	5 (2)
			Infection of wire	8 (3)	0
			Other	5 (2)	8 (3)
Total rate of adverse events			78 (29)	3 (1)	
Rate of serious adverse events			73 (27)	8 (3)	

PEG, percutaneous endoscopic gastrostomy; PIG, per-oral image-guided gastrostomy.

**Table 3.** Procedure-Associated Mortality and Adverse Events in Cohort Studies of Amyotrophic Lateral Sclerosis Patients

Author (yr)	No. of subjects	Follow-up duration (yr)	Type of adverse event	Number of events (% , n)	Management
Procedure-associated mortality					
Kotan, et al. (2016) <sup>17</sup>	1	1	Procedure-related mortality	0	NA
Unders, et al. (2009) <sup>19</sup>	38	7	Perioperative mortality	0	NA
Complications and adverse events					
Rezania, et al. (2014) <sup>18</sup>	10	1	Deep vein thrombosis, pulmonary thromboembolism	20 (2/10)	Warfarin, enoxaparin
Unders, et al. (2009) <sup>19</sup>	38	7	Wound infection	2.63 (1/38)	Oral antibiotics and repositioning or reinsertion of electrode
			Capnothorax	13 (5/38)	Aspiration or observation. No hemodynamic instability or respiratory problem
			Injury to diaphragm, diaphragm laceration, solid organ damage, bleeding, bowel injury, conversion to open surgery, pneumothorax	0	NA
Kotan, et al. (2016) <sup>17</sup>	1	1	Failure of device implantation	0 (0/1)	NA

NA, no data available.



However, wound infection was reported in 2% of cases, with one study reporting capnothorax in 42% of cases.<sup>19</sup> Failure of device implantation occurred 0%<sup>20</sup> and 2%<sup>19</sup> of the study subjects, respectively (Table 4).

## Efficacy

### *Amyotrophic lateral sclerosis*

Two RCTs<sup>15,16</sup> reported the efficacy of diaphragm pacing in pa-

tients with ALS. Both studies reported shorter survival in the intervention (with DPS) and control (without diaphragm pacing) groups; there was no significant differences in terms of quality of life (Table 5).<sup>15</sup> A cohort study reported sleep quality assessment parameters at a median follow-up of 4 months after implantation of the device,<sup>21</sup> and while there were improvements in some parameters, the Epworth sleepiness score and apnea-hypopnea index were not affected (Table 6).

**Table 4.** Safety Outcomes of Diaphragm Pacing Systems in Patients with Spinal Cord Injury

Author (yr)	No. of subjects	Follow-up duration (yr)	Level of spinal injury	Type of event	Events % (n)	Management of adverse events
Procedure-associated mortality						
Onders, et al. (2009) <sup>19</sup>	50	7	High-level, not specified	Perioperative mortality	0 (0/50)	
Complications and adverse events						
Onders, et al. (2009) <sup>19</sup>	50	7	High-level, not specified	Wound infection	2 (1/50)	Oral antibiotics, repositioning or reinsertion of electrode
				Capnothorax	42 (21/50)	Aspiration or observation. No hemodynamic instability or respiratory problems
				Injury of diaphragm, diaphragm laceration, solid organ damage, bleeding, bowel injury, conversion to open surgery, pneumothorax	0 (0/50)	NA
Failure rate of device implantation						
Onders, et al. (2011) <sup>20</sup>	5	1	C1 (1), C2-C3 (3), C4-C6 (1)	Failure of device implantation	0 (0/5)	NA
Onders, et al. (2009) <sup>19</sup>	50	7	High-level, not specified	Failure of device implantation	2 (1/50)	NA

C, cervical spine; NA, no data available.

**Table 5.** Efficacy Outcomes of Diaphragm Pacing Systems in Amyotrophic Lateral Sclerosis Patients

Author (yr)	No. of subjects	Parameter	Follow-up duration (yr)	Intervention group (months)	Control group (months)	HR (95% CI)	p value
Survival							
Gonzalez-Bermejo, et al. (2016) <sup>16</sup>	74	NIV free survival since randomization	3.75	6.0 (3.6–8.7)	8.8 (4.2~ not reached)	1.96 (1.08–3.56)	0.02
	74	Overall survival since randomization		15.6 (9–27)	Not reached (>33)	3.14 (1.31–7.53)	0.007
DiPALS writing Committee (2015) <sup>15</sup>	74	Median survival	1	11.0 (8.3–13.6)	22.5 (13.6~ not reached)	2.27 (1.22–4.25)	0.009
	74	Tracheostomy-free survival		11.0 (8.3–13.6)	22.5 (13.6~ not reached)	2.42 (1.28–4.59)	0.007
Quality of life							
DiPALS writing Committee (2015) <sup>15</sup>	74	SF-36* total physical health average point	1	23.8 (12.2)	21.3 (12.0)	0.3 (-2.0–2.7)	0.789
		SF-36 total psychological health average point		42.7 (16.5)	47.7 (17.8)	-3.5 (-7.9–0.8)	0.112
		SAQLI† average point		3.9 (1.6)	4.6 (1.5)	-0.3 (-0.7–0.1)	0.117
		Caregiver Burden Inventory average point		28.0 (9.0)	29.6 (11.9)	1.2 (-2.7–5.0)	0.558

HR, hazard ratio; NIV, non-invasive ventilation; CI, confidence interval.

\*Short form-36 is a health status profile used to measure health states of patients,<sup>38</sup> †the Calgary Sleep Apnea Quality of Life Index, is a questionnaire for recording and evaluating health-related quality of life.<sup>39</sup>

**Table 6.** Sleep and Respiration Outcomes in Amyotrophic Lateral Sclerosis

Author (yr)	No. of subjects	Parameters	Difference-month 3 to month 7 <sup>1</sup>	p value
Sleep improvement				
Gonzalez-Bermejo, et al. (2012) <sup>21</sup>	18	Epworth sleepiness score* (0–24)	-0.8±3.1 (-2.0)	0.0745
		Total sleep duration (minute)	-42±107 (-19)	0.0969
		Total sleep time (minute)	26±104 (35)	0.6013
		Sleep efficacy (%)	8±12 (9)	0.0394
		Sleep incubation period (minute)	11±52 (5)	0.3829
		Stage N1-N2 (% of total sleep time)	0.1±12.1 (0.9)	0.9229
		Stage N3 (% of total Sleep time)	1.3±10.3 (4.6)	0.9068
		REM (% of total sleep time)	-1.4±6.9 (-0.5)	0.4748
		Arousal after sleep (time)	-59±73 (-69)	0.0032
		Arousal index (per h)	-6±7 (-7)	0.0005
		Apnea-hypopnea index (per h)	-4±10 (-1)	0.1196
		REM apnea-hypopnea index (per h)	-7.4±15.8 (-1.8)	0.045
		Use of cervical muscle (% of total sleep period)	-5.2±9.3 (-3.8)	0.0093
		Time spent with SpO <sub>2</sub> less than 90% (% of total sleep period)	1.4±4.3 (0.0)	0.2661
Improvement of respiration				
Gonzalez-Bermejo, et al. (2012) <sup>21</sup>	18	ALSFRS-R	-4.9±6.1 (-1.0)	0.0032
		FVC (% predicted)	-9.4±10.8 (-8.5)	0.0024
		ERV (% predicted)	-14.1±21.4 (-11.5)	0.0134
		RV (% predicted)	-10.3±21.2 (-5.8)	0.0817
		SNIP (% predicted)	-9.1±8.6 (-8.0)	0.001
		Pi, max (% predicted)	-6.1±16.8 (0)	0.351
		Pe, max (% predicted)	-6.3± 7.6 (-6.5)	0.0027
		Pes, twitch with BAMPS (cmH <sub>2</sub> O)	-2.5±3.5 (-1.8)	0.0055
		Pga, twitch with BAMPS (cmH <sub>2</sub> O)	-1.4±2.0 (-0.9)	0.016
		Pdi, twitch with BAMPS (cmH <sub>2</sub> O)	-3.6±4.9 (-2.5)	0.0009

REM, rapid eye movement; ALSFRS-R, amyotrophic lateral sclerosis functional rating scale; FVC, forced vital capacity; ERV, expiratory reserve volume; SNIP, sniff nasal inspiratory pressure; Pi, max, maximal static inspiratory pressure measured at the mouth; Pe, max, maximal static expiratory pressure measured at the mouth; Pes, esophageal pressure; BAMPS, bilateral anterior magnetic stimulation; Pga, gastric pressure; Pdi, transdiaphragmatic pressure.

\*The Epworth sleepiness scale is a subjective measurement of sleepiness; scores higher than 10 points may require medical attention,<sup>40</sup> <sup>1</sup>Month 3 was the time of baseline and month 7 was the time of 4 months after device implantation and diaphragm conditioning.

**Spinal cord injury**

Only one study<sup>22</sup> compared overall survival between intervention (diaphragm pacing) and control groups in patients with spinal cord injury. This retrospective study reviewed 25 years of follow-up data for 55 patients with spinal cord injury requiring mechanical ventilation. Of the 55 patients, 19 patients received diaphragm pacing with mechanical ventilation, while the remaining 36 patients received mechanical ventilation only. The overall survival did not differ significantly between groups when stratified by age (Table 7). Mechanical ventilator weaning was successful in 33% (2/6) and 96% (48/50) cases in a pediatric case series and an adult prospective cohort, respectively (Table 8).

**DISCUSSION**

DPSs assist patient respiration through electrical stimulation

of the diaphragm. Several text books<sup>23-25</sup> have recommended it as a treatment option for respiratory failure in spinal cord injury, ALS, and sleep apnea.

To date, the only known medication that prolongs survival in patients with ALS is riluzole,<sup>26</sup> but its effects are limited. Therefore, supportive treatments, such as non-invasive mechanical ventilation, for neurological dysfunction are important in ALS management<sup>27</sup> and can improve patient survival and quality of life.<sup>28</sup> However, mechanical ventilation is burdensome to maintain; hence, patients can become discouraged to use it consistently. Diaphragm pacing may, thus, be a more attractive option for supportive management of respiration since it is an implantable device that allows more physical activity and mobility than non-invasive ventilation. Although the FDA has approved the use of the technology and promising results have been reported in patients with spinal cord injury, some studies have reported disappointing results in patients with ALS.

Diaphragm pacing has been conducted by different tech-

**Table 7.** Overall Survival in Spinal Cord Injury Patients after Diaphragm Pacing System

Author (yr)	No. of subjects	Follow-up duration (yr)	Age (years)	Mean survival duration, months (No. of patients)		p value
				Intervention group* (n=19)	Control group† (n=36)	
Watt, et al. (2011) <sup>22†</sup>	55	25	0–30	19.2 (13)	17.4 (12)	0.142
			30–45	3.2 (3)	9.9 (12)	0.129
			46+	10.3 (3)	7.9 (12)	0.860

\*diaphragm pacing (full or part time), †mechanical ventilation only, ‡Retrospective study of spinal cord injury patients with mechanical ventilation. The comparison was between subjects with diaphragm pacing and mechanical ventilation and those with mechanical ventilation alone.

**Table 8.** Ventilator Weaning in Patients with Spinal Cord Injury

Author (yr)	No. of subjects	Follow-up duration (yr)	Level of spinal injury (No. of patients)	Ventilator weaning, % (No. of patients, person/total)
Onders, et al. (2011) <sup>20*</sup>	6	1	C1 (1), C2-C3 (3), C4-C6 (1)	33 (2/6)
Onders, et al. (2009) <sup>19</sup>	50	7	NA	96 (48/50)

C, cervical spine; NA, no data available.

\*The subjects of this study were pediatric patients.

niques and devices. Moreover, various definitions and measurements of study outcomes have led to inconsistent study results in terms of safety and efficacy. In this systematic review, we aimed to evaluate the efficacy and safety of a technique in which electrodes are implanted into the diaphragm muscle (diaphragm pacing) and provide information to clinicians regarding whether diaphragm pacing should be recommended to patients. Hence, we only included studies that used similar devices and implantation techniques (laparoscopic procedure), had limited target conditions (ALS and spinal cord injury), and assessed well-defined clinical outcomes (efficacy and safety).

The RCT<sup>15</sup> involving patients with ALS reported that complications and adverse events were higher in the intervention group (with diaphragm pacing) than in the control group (without diaphragm pacing). This was expected in studies, such as the DiPALS study,<sup>15</sup> where a surgical procedure was only conducted in the intervention group. In the RespiStimALS study<sup>16</sup> that used a sham surgical intervention in controls, there were no significant differences in respiratory complications or complications related to the surgical procedures (capnothorax or pneumothorax, acute respiratory failure). Overall complication rates were 78% in DiPALS study (intervention group) and 59% (active stimulation) and 65% (sham stimulation) in the RespiStimALS study, which are much higher than that in individuals without a procedure (3% in DiPALS study). Owing to the already high perioperative and postoperative risks of surgery in patients with ALS, the surgical process of diaphragm pacing implantation may increase the risk of procedure-related mortality and complications.<sup>29–31</sup>

The two cohort studies<sup>19,20</sup> involving patients with cervical spinal cord injury did not report procedure-related mortality or device implantation failures. Failure of device implantation was relatively low: this may have been related to the physicians' experience and patient volume of the center. However, because of the limited number of studies that were eligible for this review, solid recommendations cannot be made about the safe-

ty of diaphragm pacing in patients with cervical spinal cord injury.

Studies involving patients with ALS showed different results than those involving patients with spinal cord injury. Patients in the intervention group (diaphragm pacing) had a shorter survival than those in the control group in both randomized controlled studies.<sup>15,16</sup> The DiPALS study<sup>15</sup> included patients with ALS who required non-invasive support due to respiratory insufficiency and showed disappointing overall survival in the intervention group. The RespiStimALS study,<sup>16</sup> which included patients with moderate respiratory dysfunction who were not requiring non-invasive ventilation, also showed worse overall survival in the diaphragm pacing group. This suggested that the timing of the intervention and residual respiratory functions did not affect the clinical outcome of the studies. Additional analyses of the RespiStimALS data showed that the level of involved neurons did not affect survival outcomes in patients who received a DPS.<sup>32</sup> The study populations of the RCTs were similar to those of the studies reviewed by the FDA before approving the DPS; however, the efficacy outcomes were different.<sup>33</sup>

Quality of life was not significantly different between patients receiving the DPS plus non-invasive ventilation and those receiving non-invasive ventilation alone.<sup>15</sup> Sleep improvement was reported in terms of 14 sleep-related variables, five of which showed improvement.<sup>21</sup> However, the apnea-hypopnea index, the most clinically important indicator, was not significantly different between the intervention and control groups. Furthermore, with regard to respiratory function, forced vital capacity decreased after implantation of the DPS.<sup>21</sup> Overall, DPS does not appear to have clinical efficacy in patients with ALS.

The studies involving patients with spinal cord injury<sup>22</sup> found that survival duration was not significantly different between diaphragm pacing and no diaphragm pacing. The rate of mechanical ventilation weaning in patients with spinal cord injury was reported in one cohort study and one case series as 33%<sup>20</sup>



and 96%,<sup>19</sup> respectively. However, with regard to quality assessment, given that one study was only a case series, the results remain inconclusive. Additional well-designed studies are required to ascertain the efficacy of DPS in patients with spinal cord injuries.

Garara, et al.<sup>34</sup> published a systematic review on the safety and efficacy of diaphragm pacing in ventilator-dependent patients with high cervical injuries. They suggested that the treatment was safe because the complications were less severe, the device only required simple management, and the treatment was efficient, allowing the patients to be weaned of the ventilator. Owing to the generally low quality and limited number of subjects in available studies, our systematic review did not reach a firm conclusion that diaphragm pacing in high cervical spinal cord injuries should be accepted as validated management.

A strength of this systematic review was that we included studies using similar intervention techniques (laparoscopic procedure, DPS) to diminish the heterogeneity of results. There are, however, several limitations. First, most of the studies included were not high-level studies with strong methodologies: only two randomized controlled studies were eligible for inclusion in the analysis. Second, because of the overall limited number of studies, some clinical outcomes (e.g., sleep-associated outcomes, overall survival of spinal cord injury) were extracted from a single study. Thus, it is difficult to draw a robust conclusion about the clinical outcomes.

DPS are frequently used as short- or long-term alternatives to mechanical ventilation in patients with ALS. Results from this systematic review, however, suggest that diaphragm pacing recipients experience more complications and adverse events and are less likely to show an improvement in clinical outcomes than non-recipients. Our synthesis of the literature does not recommend the use of DPS to manage respiratory failure in patients with ALS or cervical spinal cord injuries. Further comprehensive studies, including RCTs, are needed to adequately evaluate the efficacy and safety profile of this technique.

## ACKNOWLEDGEMENTS

This research was supported by New Technology Assessment, National Evidence-based Healthcare Collaborating Agency.

## AUTHOR CONTRIBUTIONS

**Conceptualization:** Chae-Man Lim, Ha-jin Tchoe, Hae-won Shin, and Chae-min Shin. **Data curation:** Ha-jin Tchoe, Hae-won Shin, and Chae-min Shin. **Formal analysis:** Ha-jin Tchoe, Hae-won Shin, and Chae-min Shin. **Funding acquisition:** Ha-jin Tchoe, Hae-won Shin, and Chae-min Shin. **Investigation:** Ha-jin Tchoe, Hae-won Shin, and Chae-min Shin. **Methodology:** Ha-jin Tchoe, Hae-won Shin, and Chae-min Shin. **Project administration:** Ha-jin Tchoe, Hae-won Shin, and Chae-min Shin. **Resources:** Ha-jin Tchoe, Hae-won Shin, and Chae-min Shin. **Software:** A-la Woo. **Supervision:** Chae-Man Lim. **Validation:** A-la Woo. **Visualization:** A-la Woo. **Writing—original draft:**

A-la Woo. **Writing—review & editing:** A-la Woo and Chae-Man Lim. **Approval of final manuscript:** all authors.

## ORCID iDs

A-la Woo <https://orcid.org/0000-0002-8818-6115>  
 Ha-jin Tchoe <https://orcid.org/0000-0001-6830-499X>  
 Hae-won Shin <https://orcid.org/0000-0002-3394-0803>  
 Chae-min Shin <https://orcid.org/0000-0001-7970-565X>  
 Chae-Man Lim <https://orcid.org/0000-0001-5400-6588>

## REFERENCES

- Lechtzin N. Respiratory effects of amyotrophic lateral sclerosis: problems and solutions. *Respir Care* 2006;51:871-84.
- Lo V, Esquenazi Y, Han MK, Lee K. Critical care management of patients with acute spinal cord injury. *J Neurosurg Sci* 2013;57:281-92.
- Berlowitz DJ, Howard ME, Fiore JF Jr, Vander Hoom S, O'Donoghue FJ, Westlake J, et al. Identifying who will benefit from non-invasive ventilation in amyotrophic lateral sclerosis/motor neurone disease in a clinical cohort. *J Neurol Neurosurg Psychiatry* 2016;87:280-6.
- Clinical indications for noninvasive positive pressure ventilation in chronic respiratory failure due to restrictive lung disease, COPD, and nocturnal hypoventilation--a consensus conference report. *Chest* 1999;116:521-34.
- Morelot-Panzini C, Bruneteau G, Gonzalez-Bermejo J. NIV in amyotrophic lateral sclerosis: the 'when' and 'how' of the matter. *Respirology* 2019;24:521-30.
- Sancho J, Servera E, Díaz JL, Bañuls P, Marín J. Home tracheotomy mechanical ventilation in patients with amyotrophic lateral sclerosis: causes, complications and 1-year survival. *Thorax* 2011;66:948-52.
- Splaingard ML, Frates RC Jr, Harrison GM, Carter RE, Jefferson LS. Home positive-pressure ventilation. Twenty years' experience. *Chest* 1983;84:376-82.
- Corcia P, Pradat PF, Salachas F, Bruneteau G, Le Forestier N, Seilhean D, et al. Causes of death in a post-mortem series of ALS patients. *Amyotrophic Lateral Scler* 2008;9:59-62.
- Glenn WW, Holcomb WG, Hogan J, Matano I, Gee JB, Motoyama EK, et al. Diaphragm pacing by radiofrequency transmission in the treatment of chronic ventilatory insufficiency: present status. *J Thorac Cardiovasc Surg* 1973;66:505-20.
- Gonzalez-Bermejo J, LLontop C, Similowski T, Morélot-Panzini C. Respiratory neuromodulation in patients with neurological pathologies: for whom and how? *Ann Phys Rehabil Med* 2015;58:238-44.
- Onders RP, Elmo M, Kaplan C, Katirji B, Schilz R. Final analysis of the pilot trial of diaphragm pacing in amyotrophic lateral sclerosis with long-term follow-up: diaphragm pacing positively affects diaphragm respiration. *Am J Surg* 2014;207:393-7.
- Boentert M. Sleep disturbances in patients with amyotrophic lateral sclerosis: current perspectives. *Nat Sci Sleep* 2019;11:97-111.
- Scherer K, Bedlack RS. Diaphragm pacing in amyotrophic lateral sclerosis: a literature review. *Muscle Nerve* 2012;46:1-8.
- Arnulf I, Similowski T, Salachas F, Garma L, Mehiri S, Attali V, et al. Sleep disorders and diaphragmatic function in patients with amyotrophic lateral sclerosis. *Am J Respir Crit Care Med* 2000;161:849-56.
- DiPALS Writing Committee; DiPALS Study Group Collaborators. Safety and efficacy of diaphragm pacing in patients with respiratory insufficiency due to amyotrophic lateral sclerosis (DiPALS): a

- multicentre, open-label, randomised controlled trial. *Lancet Neurol* 2015;14:883-92.
16. Gonzalez-Bermejo J, Morélot-Panzini C, Tanguy ML, Meininger V, Pradat PF, Lenglet T, et al. Early diaphragm pacing in patients with amyotrophic lateral sclerosis (RespiStimALS): a randomised controlled triple-blind trial. *Lancet Neurol* 2016;15:1217-27.
  17. Kotan D, Kaymak K, Gündogdu AA. Diaphragm pacing system implanted in a patient with ALS. *J Back Musculoskelet Rehabil* 2016;29:611-2.
  18. Rezania K, Gottlieb O, Guralnick A, Prachand V, Sweitzer BJ, Vigneswaran W, et al. Venous thromboembolism after diaphragm pacing in amyotrophic lateral sclerosis. *Muscle Nerve* 2014;50:863-5.
  19. Onders RP, Elmo M, Khansarinia S, Bowman B, Yee J, Road J, et al. Complete worldwide operative experience in laparoscopic diaphragm pacing: results and differences in spinal cord injured patients and amyotrophic lateral sclerosis patients. *Surg Endosc* 2009;23:1433-40.
  20. Onders RP, Ponsky TA, Elmo M, Lidsky K, Barksdale E. First reported experience with intramuscular diaphragm pacing in replacing positive pressure mechanical ventilators in children. *J Pediatr Surg* 2011;46:72-6.
  21. Gonzalez-Bermejo J, Morélot-Panzini C, Salachas F, Redolfi S, Straus C, Becquemin MH, et al. Diaphragm pacing improves sleep in patients with amyotrophic lateral sclerosis. *Amyotroph Lateral Scler* 2012;13:44-54.
  22. Watt JW, Wiredu E, Silva P, Meehan S. Survival after short- or long-term ventilation after acute spinal cord injury: a single-centre 25-year retrospective study. *Spinal Cord* 2011;49:404-10.
  23. Ducko CT. Diaphragm pacing. In: Sugarbaker DJ, Bueno R, Colson YL, Jaklitsch MT, Krasna MJ, Mentzer SJ, editors. *Adult chest surgery*. 2nd ed. New York: McGraw-Hill Education; 2015. p.1214-20.
  24. Onders RP. Diaphragm pacing for acute respiratory failure. In: Ferguson MK, editor. *Difficult decisions in thoracic surgery: an evidence-based approach*. 2nd ed. Springer; 2011. p.329-33.
  25. Onders RP. Stimulation for inspiration. In: Krames ES, Peckham PH, Rezai AR, editors. *Neuromodulation: comprehensive textbook of principles, technologies, and therapies*. 2nd ed. Academic Press; 2018. p.1347-54.
  26. Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). *Cochrane Database Syst Rev* 2012;2012:CD001447.
  27. Hobson EV, McDermott CJ. Supportive and symptomatic management of amyotrophic lateral sclerosis. *Nat Rev Neurol* 2016;12:526-38.
  28. Bourke SC, Tomlinson M, Williams TL, Bullock RE, Shaw PJ, Gibson GJ. Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. *Lancet Neurol* 2006;5:140-7.
  29. Short SO, Hillel AD. Palliative surgery in patients with bulbar amyotrophic lateral sclerosis. *Head Neck* 1989;11:364-9.
  30. Pinto S, Swash M, de Carvalho M. Does surgery accelerate progression of amyotrophic lateral sclerosis? *J Neurol Neurosurg Psychiatry* 2014;85:643-6.
  31. Hoepfer AM, Barbara DW, Watson JC, Sprung J, Weingarten TN. Amyotrophic lateral sclerosis and anesthesia: a case series and review of the literature. *J Anesth* 2019;33:257-65.
  32. Morélot-Panzini C, Nierat MC, Tanguy ML, Bruneteau G, Pradat PF, Salachas F, et al. No benefit of diaphragm pacing in upper motor neuron-dominant forms of amyotrophic lateral sclerosis. *Am J Respir Crit Care Med* 2018;198:964-8.
  33. US Food and Drug Administration. Humanitarian Device Exemption Database. *NeurRx DPS, Diaphragm Pacing System—Summary of safety and probable benefit (no. H100006)* [accessed on 2020 September 18]. Available from: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfhde/hde.cfm?id=375558>.
  34. Garara B, Wood A, Marcus HJ, Tsang K, Wilson MH, Khan M. Intramuscular diaphragmatic stimulation for patients with traumatic high cervical injuries and ventilator dependent respiratory failure: a systematic review of safety and effectiveness. *Injury* 2016;47:539-44.
  35. Synapse Biomedical. *NeuRx Diaphragm Pacing System™: patient/caregiver instruction manual* [accessed on 2020 September 18]. Available from: [https://www.synapsebiomedical.com/wp-content/uploads/2017/09/2017\\_SCI\\_Caregiver\\_Manual.pdf](https://www.synapsebiomedical.com/wp-content/uploads/2017/09/2017_SCI_Caregiver_Manual.pdf).
  36. Bolikal P, Bach JR, Goncalves M. Electrophrenic pacing and decannulation for high-level spinal cord injury: a case series. *J Spinal Cord Med* 2012;35:170-4.
  37. Epstein SW, Vanderlinden RG, Man SF, Hyland RH, Lenkei SC, Wise DJ, et al. Lung function in diaphragm pacing. *Can Med Assoc J* 1979;120:1360-8.
  38. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. *Med Care* 1992;30:473-83.
  39. Flemons WW, Reimer MA. Development of a disease-specific health-related quality of life questionnaire for sleep apnea. *Am J Respir Crit Care Med* 1998;158:494-503.
  40. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. *Sleep* 1991;14:540-5.